{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:38:20Z","timestamp":1791970700651,"version":"4.3.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.micpath.2025.108018","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:56:17Z","timestamp":1757001377000},"page":"108018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Integrative strategies against multidrug-resistant bacteria: Synthesizing novel antimicrobial frontiers for global health"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-7505","authenticated-orcid":false,"given":"Jaishriram","family":"Rathored","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanushree","family":"Budhbaware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.micpath.2025.108018_bib1","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3390\/healthcare11131946","article-title":"Antimicrobial resistance: a growing serious threat for global public health","volume":"11","author":"Salam","year":"2023","journal-title":"Healthcare"},{"issue":"4","key":"10.1016\/j.micpath.2025.108018_bib3","first-page":"277","article-title":"The antibiotic resistance crisis","volume":"40","author":"Ventola","year":"2015","journal-title":"Pharm. Ther."},{"issue":"7\u20138","key":"10.1016\/j.micpath.2025.108018_bib4","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s00018-007-6475-6","article-title":"Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections","volume":"64","author":"Mookherjee","year":"2007","journal-title":"Cell. Mol. Life Sci. CMLS"},{"issue":"2","key":"10.1016\/j.micpath.2025.108018_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4161\/bact.1.2.15845","article-title":"Phage treatment of human infections","volume":"1","author":"Abedon","year":"2011","journal-title":"Bacteriophage"},{"key":"10.1016\/j.micpath.2025.108018_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mib.2017.08.005","article-title":"Using CRISPR-cas systems as antimicrobials","volume":"37","author":"Bikard","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"issue":"13\u201314","key":"10.1016\/j.micpath.2025.108018_bib7","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.addr.2013.07.011","article-title":"Nanotechnology as a therapeutic tool to combat microbial resistance","volume":"65","author":"Pelgrift","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7535","key":"10.1016\/j.micpath.2025.108018_bib8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature14098","article-title":"A new antibiotic kills pathogens without detectable resistance","volume":"517","author":"Ling","year":"2015","journal-title":"Nature"},{"issue":"9997","key":"10.1016\/j.micpath.2025.108018_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle East respiratory syndrome","volume":"386","author":"Zumla","year":"2015","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.micpath.2025.108018_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.glmedi.2024.100081","article-title":"Antimicrobial resistance: impacts, challenges, and future prospects","volume":"2","author":"Ahmed","year":"2024","journal-title":"J. Med. Surg. Public Health"},{"issue":"6","key":"10.1016\/j.micpath.2025.108018_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/138920306779025620","article-title":"Host defense peptides and lipopeptides: Modes of action and potential candidates for the treatment of bacterial and fungal infections","volume":"7","author":"Shai","year":"2006","journal-title":"Curr. Protein Pept. Sci."},{"issue":"1","key":"10.1016\/j.micpath.2025.108018_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/biom8010004","article-title":"Antimicrobial peptides: diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo","volume":"8","author":"Kumar","year":"2018","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.micpath.2025.108018_bib13","first-page":"128","article-title":"Pexiganan in combination with nisin to control polymicrobial diabetic foot infections","volume":"9","author":"Gomes","year":"2020","journal-title":"Antibiot. Basel Switz."},{"issue":"8","key":"10.1016\/j.micpath.2025.108018_bib14","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.bbamem.2008.10.009","article-title":"Structure, membrane orientation, mechanism, and function of pexiganan \u2013 a highly potent antimicrobial peptide designed from magainin","volume":"1788","author":"Gottler","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.micpath.2025.108018_bib15","author":"Hardalo"},{"issue":"2","key":"10.1016\/j.micpath.2025.108018_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/v13020271","article-title":"Brilacidin demonstrates inhibition of SARS-CoV-2 in cell culture","volume":"13","author":"Bakovic","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.micpath.2025.108018_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.582779","article-title":"Antimicrobial peptides: classification, design, application and research progress in multiple fields","volume":"11","author":"Huan","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.micpath.2025.108018_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/BTT.S381237","article-title":"Phage therapy: a different approach to fight bacterial infections","volume":"16","author":"Hibstu","year":"2022","journal-title":"Biol. Targets & Ther."},{"issue":"3","key":"10.1016\/j.micpath.2025.108018_bib21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","article-title":"Phage therapy: an alternative to antibiotics in the age of multi-drug resistance","volume":"8","author":"Lin","year":"2017","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"10.1016\/j.micpath.2025.108018_bib22","doi-asserted-by":"crossref","unstructured":"Sahoo, K.; Meshram, S. The evolution of phage therapy: a comprehensive review of current applications and future innovations. Cureus 16 (9), e70414. https:\/\/doi.org\/10.7759\/cureus.70414.","DOI":"10.7759\/cureus.70414"},{"issue":"12","key":"10.1016\/j.micpath.2025.108018_bib23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3390\/ph16121638","article-title":"Phage therapy\u2014challenges, opportunities and future prospects","volume":"16","author":"Zalewska-Pi\u0105tek","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.micpath.2025.108018_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter Baumannii infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.micpath.2025.108018_bib27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/23744235.2024.2379492","article-title":"Phage therapy: an alternative treatment modality for MDR bacterial infections","volume":"56","author":"Pal","year":"2024","journal-title":"Infect. Dis."},{"key":"10.1016\/j.micpath.2025.108018_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.microb.2025.100344","article-title":"CRISPR cas systems: from bacterial defense mechanisms to revolutionary tools reshaping genetic research and translation therapeutics","volume":"7","author":"Saeed","year":"2025","journal-title":"Microbe"},{"key":"10.1016\/j.micpath.2025.108018_bib29","article-title":"Recent advances of CRISPR-based genome editing for enhancing staple crops","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Plant Sci."},{"issue":"7","key":"10.1016\/j.micpath.2025.108018_bib30","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/acsinfecdis.2c00649","article-title":"CRISPR-Cas-Based antimicrobials: design, challenges, and bacterial mechanisms of resistance","volume":"9","author":"Mayorga-Ramos","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.micpath.2025.108018_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.716064","article-title":"Harnessing the CRISPR-Cas systems to combat antimicrobial resistance","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108018_bib32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41467-021-27656-z","article-title":"Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella Pneumoniae","volume":"13","author":"Eskenazi","year":"2022","journal-title":"Nat. Commun."},{"issue":"13\u201314","key":"10.1016\/j.micpath.2025.108018_bib33","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.addr.2013.07.011","article-title":"Nanotechnology as a therapeutic tool to combat microbial resistance","volume":"65","author":"Pelgrift","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.micpath.2025.108018_bib35","series-title":"Development of Phage Resistance in Multidrug-Resistant Klebsiella pneumoniae is Associated with Reduced Virulence: a Case Report of a Personalised Phage Therapy","year":"2025"},{"issue":"3","key":"10.1016\/j.micpath.2025.108018_bib36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"issue":"12","key":"10.1016\/j.micpath.2025.108018_bib37","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/ph17121711","article-title":"Nanotechnology for healthcare: plant-derived nanoparticles in disease treatment and regenerative medicine","volume":"17","author":"Karnwal","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.micpath.2025.108018_bib38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/pharmaceutics16030396","article-title":"Lipid nanocarriers-enabled delivery of antibiotics and antimicrobial adjuvants to overcome bacterial biofilms","volume":"16","author":"Ahsan","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.micpath.2025.108018_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106515","article-title":"Nanoparticles-based therapeutics for the management of bacterial infections: a special emphasis on FDA approved products and clinical trials","volume":"188","author":"Aflakian","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.micpath.2025.108018_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.327","article-title":"Nanoparticles\u2010induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models","volume":"4","author":"Xuan","year":"2023","journal-title":"MedComm"},{"issue":"4","key":"10.1016\/j.micpath.2025.108018_bib41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11051-025-06290-6","article-title":"The current use of nanotechnology in the fight against antimicrobial resistance: promising approaches to global health challenge","volume":"27","author":"Mmbando","year":"2025","journal-title":"J. Nanoparticle Res."},{"issue":"1","key":"10.1016\/j.micpath.2025.108018_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.micpath.2025.108018_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41577-022-00734-z","article-title":"Host-directed immunotherapy of viral and bacterial infections: past, present and future","volume":"23","author":"Wallis","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.micpath.2025.108018_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1127704","article-title":"Immunomodulation\u2014A general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system","volume":"14","author":"Strzelec","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2025.108018_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107130","article-title":"Host-directed therapies: old and new approaches for the treatment of infections","volume":"146","author":"Goletti","year":"2024","journal-title":"Int. J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.micpath.2025.108018_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.slast.2024.100120","article-title":"Employing synthetic biology to expand antibiotic discovery","volume":"29","author":"Cook","year":"2024","journal-title":"SLAS Technol."},{"key":"10.1016\/j.micpath.2025.108018_bib47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2105-4-41","article-title":"The COG database: an updated version includes eukaryotes","volume":"4","author":"Tatusov","year":"2003","journal-title":"BMC Bioinf."},{"issue":"5","key":"10.1016\/j.micpath.2025.108018_bib48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/metabo13050625","article-title":"High-throughput screening of natural product and synthetic molecule libraries for antibacterial drug discovery","volume":"13","author":"Ayon","year":"2023","journal-title":"Metabolites"},{"issue":"11","key":"10.1016\/j.micpath.2025.108018_bib49","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3390\/ph16111615","article-title":"Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review","volume":"16","author":"Muteeb","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.micpath.2025.108018_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00924-21","article-title":"Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination","volume":"65","author":"Zaidan","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.micpath.2025.108018_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1432703","article-title":"Phage therapy for extensively drug resistant Acinetobacter Baumannii infection: case report and in vivo evaluation of the distribution of phage and the impact on Gut Microbiome","volume":"11","author":"Qu","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.micpath.2025.108018_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116077","article-title":"Antistaphylococcal discovery pipeline; where are we now?","volume":"266","author":"Nawrot","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.micpath.2025.108018_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01879-21","article-title":"Prospective activity of PLG0206, an engineered antimicrobial peptide, on chronic periprosthetic joint infection total knee arthroplasty components Ex vivo: the knee explant analysis (KnEA) study","volume":"9","author":"Huang","year":"2021","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.micpath.2025.108018_bib55","author":"Pharmaceutica"},{"key":"10.1016\/j.micpath.2025.108018_bib56","unstructured":"Safety and pharmacokinetic characterization of nacubactam, a novel \u03b2-Lactamase inhibitor, alone and in combination with Meropenem, in Healthy Volunteers. https:\/\/ichgcp.net\/clinical-trials-registry\/publications\/147390-safety-and-pharmacokinetic-characterization-of-nacubactam-a-novel-v-lactamase-inhibitor-alone-and-in?utm_source=chatgpt.com (accessed 2025-August-6)."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025007430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401025007430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:24:36Z","timestamp":1758583476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401025007430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":49,"alternative-id":["S0882401025007430"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2025.108018","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrative strategies against multidrug-resistant bacteria: Synthesizing novel antimicrobial frontiers for global health","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2025.108018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108018"}}